Christopher Michael Chipman - 25 Jan 2023 Form 4 Insider Report for Virpax Pharmaceuticals, Inc. (VRPX)

Role
Chief Financial Officer
Signature
/s/ Christopher Chipman
Issuer symbol
VRPX
Transactions as of
25 Jan 2023
Net transactions value
$0
Form type
4
Filing time
27 Jan 2023, 19:30:14 UTC
Previous filing
25 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRPX Stock Option (right to buy) Award $0 +112,000 $0.000000 112,000 25 Jan 2023 Common Stock 112,000 $0.7880 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in three equal annual installments commencing on January 25, 2024.